SELENBP1

Across TCGA pan-cancer cohorts, SELENBP1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SELENBP1 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SELENBP1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SELENBP1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SELENBP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.670	0.406	<.001	103	view →
CCRCC	OS	Tertile	All	0.970	0.693	<.001	44	view →
LUAD	OS	Median	All	1.000	0.764	.004	21	view →
GBM	OS	Median	All	0.269	0.481	.002	8	view →
HNSC	OS	Tertile	II,III,IV	0.928	1.000	.018	6	view →
LSCC	DFS	Quartile	All	1.000	0.810	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SELENBP1–PDAC (OS)

Open the PDAC breakdown →